Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis
Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Marco Cosentino(University of Insubria), Franca Marino(University of Insubria), Gıancarlo Comı(Casa di Cura Columbus), Sergio Lecchini(University of Insubria), Emanuela Rasini(University of Insubria), Marco Ferrari(University of Insubria), Marta Monti(University of Insubria), R Bombelli(University of Insubria), Angelo Ghezzi
Cited by 56
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624